Results 71 to 80 of about 74,631 (338)

Effects of dance therapy on balance, gait and neuro-psychological performances in patients with Parkinson's disease and postural instability [PDF]

, 2012
Postural Instability (PI) is a core feature of Parkinson’s Disease (PD) and a major cause of falls and disabilities. Impairment of executive functions has been called as an aggravating factor on motor performances. Dance therapy has been shown effective
Agnetti, Virgilio, Aiello, Elena, De Natale, Edoardo, Deriu, Franca, Paulus, Kai Stephan, Sotgiu, Giovanni, Tolu, Eusebio   +6 more
core  

Botulinum toxin type A for Holmes tremor secondary to thalamic hemorrhage [PDF]

, 2015
Holmes tremor (HT) is a low-frequency rest and intentional tremor frequently affecting the upper limb.
Giovannelli, Morena, Latino, Pamela, Orzi, Francesco, Pontieri, FRANCESCO ERNESTO   +3 more
core   +1 more source

Levodopa and Huntington's chorea [PDF]

Journal of Neurology, Neurosurgery & Psychiatry, 1976
Two patients with Huntington's chorea are reported whose psychiatric and neurological symptoms greatly improved after treatment with L-dopa. In both cases the basal values of CSF HVA were markedly decreased, being increased by the treatment with L-dopa.
Loeb C, Roccatagliata G, La Medica G, ABBRUZZESE, GIOVANNI, ALBANO, CLAUDIO   +4 more
openaire   +4 more sources

Disease Progression in Multiple System Atrophy: The ASPIRE Multi‐Modal Biomarker Study

Annals of Neurology, EarlyView.
Objective The objective of this study was to characterize changes in candidate biomarkers in early multiple system atrophy (MSA) and identify baseline predictors of faster progression. Methods This 1‐year, multicenter, prospective study assessed clinical, neuroimaging (3T‐magnetic resonance imaging [MRI], dopamine transporter single‐photon emission ...
Margherita Fabbri, Natalia del Campo, Wassilios G. Meissner, Vanessa Rousseau, Agnès Sommet, Pierre Payoux, Pierre Gantet, Amel Drif, Hélène Catalá, Claire Thalamas, Christine Tranchant, Franck Durif, Ana Marques, Alexandre Eusebio, Luc Defebvre, Jean‐Christophe Corvol, Stéphane Thobois, Anthime Flaus, Anne‐Gaelle Corbille, Solène Frismand, Beverley Patterson, Alexandra Foubert‐Samier, Anne Pavy‐Le Traon, Germain Arribarat, Patrice Péran, Olivier Rascol, for the ASPIRE Study Group   +26 more
wiley   +1 more source

Intrastriatal Memantine Infusion Dampens Levodopa-Induced Dyskinesia and Motor Deficits in a Mouse Model of Hemiparkinsonism

Frontiers in Neurology, 2019
Although the administration of dopamine precursor levodopa remains as the mainstay for the treatment of Parkinson's disease, long-term exposure to levodopa often causes a disabling complication, referred to as levodopa-induced dyskinesias. Therefore, the
Masatoshi Ogawa, Masatoshi Ogawa, Yu Zhou, Yu Zhou, Ryosuke Tsuji, Ryosuke Tsuji, Jiro Kasahara, Jiro Kasahara, Satoshi Goto, Satoshi Goto   +9 more
doaj   +1 more source

Beta Power Response After Levodopa Intake in Parkinson's Disease Patients With Chronic Sensing‐Enabled Deep Brain Stimulation

Annals of Neurology, EarlyView.
Objective In Parkinson's disease (PD), the power of beta oscillations (± 13–30 hertz [Hz]) from subthalamic nucleus (STN) local field potentials (LFPs) is associated with motor symptoms. Beta power can be used for adaptive deep brain stimulation (aDBS) algorithms based upon symptom fluctuations.
Martijn G.J. de Neeling, Bart J. Keulen, Mariëlle J. Stam, Deborah Hubers, Rob M.A. de Bie, Bernadette C.M. van Wijk, P. Rick Schuurman, Arthur W.G. Buijink, Martijn Beudel   +8 more
wiley   +1 more source

Extended-release oral capsule of carbidopa–levodopa in Parkinson disease

Therapeutic Advances in Neurological Disorders, 2018
Motor fluctuations complicate the treatment of patients with Parkinson’s disease receiving levodopa. Extended-release carbidopa–levodopa has a pharmacokinetic profile that provides a more continuous levodopa serum concentration.
Jason Margolesky, Carlos Singer
doaj   +1 more source

Treatment initiation for parkinson’s disease in Australia 2013–2018: a nation-wide study

BMC Geriatrics, 2022
Background Guidelines highlight the importance of an individualized approach to treatment initiation for Parkinson’s disease. Our aim was to investigate initiation of anti-Parkinson medication in Australia from 2013–2018, and to determine factors ...
Marjaana Koponen, J. Simon Bell, Samanta Lalic, Rosie Watson, Anne M. Koivisto, Jenni Ilomäki   +5 more
doaj   +1 more source

Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. [PDF]

, 1997
BACKGROUND: More than 50% of patients with Parkinson's disease develop motor response fluctuations (the "wearing off" phenomenon) after more than five years of levodopa therapy.
Baas, H., Beiske, A.G., Ghika, J., Jackson, M., Oertel, W.H., Poewe, W., Ransmayr, G.   +6 more
core   +1 more source

Developing the Inpatient Mental Health Pharmaceutical Assessment and Care Tool (IMPACT) for use by UK mental health pharmacy teams—a modified Delphi study

British Journal of Clinical Pharmacology, EarlyView.
Aims To develop an evidence‐ and consensus‐based patient prioritization tool for use by UK mental health inpatient pharmacy teams. Methods A modified‐Delphi technique was used to obtain experts' agreement on the content, design and practical use of the patient prioritization tool.
Fatima Q. Alshaikhmubarak, Richard N. Keers, Petra Brown, Penny J. Lewis   +3 more
wiley   +1 more source